Albert L. Sokol: Lawyer with Edwards Wildman Palmer LLP

Albert L. Sokol

View Albert L. Sokol 's Martindale-Hubbell Connected Profile
Boston,  MA  U.S.A.

Peer Rating

Client Rating

Printer Friendly VersionEmail this PageDownload to My Outlook ContactsAdd lawyer to My FavoritesCompare this lawyer to other lawyers in your favorites

Experience & Credentials

Practice Areas

  • Business Law
  • Mergers & Acquisitions
  • Private Equity
  • Venture Capital
  • Securities Offerings and Public Company Counseling
  • Licensing
  • Collaborations
  • Joint Ventures & Strategic Alliances
  • Cross Border
  • Emerging Markets
  • Life Sciences
  • Technology
  • Energy & Cleantech
  • Telecommunications
University Yale University, B.A., 1970
Law SchoolBoston University School of Law, J.D., 1977
Admitted1977, Massachusetts


Massachusetts Biotechnology Council
Massachusetts Software Council
European Venture Capital Association
Chambers of Commerce of France, Australia, Germany, Sweden, UK

BornSidney, New York, May 10, 1948

Al represents life sciences, IT/Technology and other businesses and investors in venture capital and private equity, corporate work, mergers/acquisitions, collaborations, spin-offs, strategic alliances, licenses, and management compensation issues. Much of his work involves cross-border situations. Al works hard to understand his clients' markets and business objectives.

Al has been recognized for several years by the Practical Law Company as Recommended in M&A and Corporate Transactions. He has also been listed as a Super Lawyer by Law & Politics and Boston Magazine in the areas of Securities & Venture Finance.
•For a legged robotics company that spun off from a major university 20 years ago, general corporate representation, and finally, merger with large, high-profile technology company.

•For the venture capital funds of two pharmaceutical companies (one U.S., one foreign), equity investment in a biotechnology company (oncology), having been spun off from a major research university.

•For a Swedish printed circuit board company, two separate acquisitions of U.S. competitors, one in the Northeast and the other in the Mid-West.

•For a venture-funded biotechnology company having platform IP that is used to target cancer, restructured from a single C corporation to a limited liability company (LLC), to achieve benefits of a multiple-asset-centric structure, plus assistance with financings, employee benefits, commercial issues, and other tasks.

•For a Canadian telecom equipment company (multi-wavelength laser, with advanced photonics, characterized by innovative power, size and cost parameters for data centers), venture capital financing and corporate work.

•For a venture-funded biotechnology company with platform IP for optimizing metal-binding elements of compounds, restructuring from a single C corporation to a limited liability company (LLC), to achieve benefits of a multiple-asset-centric structure, plus assistance with financings, employee benefits, commercial issues, and other tasks.

•For venture capital fund of a pharmaceutical company, many equity investments in U.S. biotechnology companies.

•For publicly traded cleantech company (composites, hardware, software), for 13 years, initial public offering, than a dozen follow-on public offerings, PIPEs and registered direct offerings, corporate counselling of company and its board of directors, multiple venture capital financings, governmentally-guaranteed loans, litigation, licensing, employment issues, and patent work.

•For a Japanese life sciences client's transaction with a U.S. company, strategic alliance covering loan, equity conversion, licensing, production and supply arrangements.

•For a venture-funded, German-based telecommunications client, during 10 years, spin off, multiple financings with UK, Belgian, Swiss, German, U.S. and Japanese investors, M&A, licensing, HR, and other work, and then an M&A exit for its sale to a U.S. telecommunications equipment company buyer.

•Sale of a Swiss life sciences services company to U.S. buyer.

•For the venture capital fund of a foreign pharmaceutical company, many equity investments in biotechnology and life sciences companies, and also a limited partner equity investment in a venture capital fund.

•Acquisition in the U.S. by a public biopharmaceutical company in Germany of an oncology diagnostics operating division of a medical devices company.

•Acquisition by a Danish engineering company of a U.S. engineering company.

•For Pacific Rim, public pharmaceutical company, and over a period of nearly 25 years, acquisition of Swedish biotech company; stock incentive arrangements in the U.S. for U.S. employees; acquisition (and, then divestment, 10 years later) of global sera and cell culture reagents business in U.S. (four states), Europe (UK and Germany) and Australia; and various licensing/IP transactions.

•Assisted many non-U.S. companies in setting up U.S. operations, in various industries, e.g., bone medical devices, pulmonary resuscitation devices, in vitro fertilization, enterprise software for financial management, asset management for financial services companies, complex resource optimization, water purity, certification of business processes, travel security, and other industries.

•For a European resource optimization software company, over a period of 6 years, acquisition of an Australian company, venture capital financing, other M&A activity, several major IT transactions in the transportation industry, and merger with large, high-profile technology company.

•Assisted various foreign banks in U.S. aspects of credit arrangements with borrowers with U.S. operations.

•For the first commercial in vitro fertilization company in the U.S., financings, corporate governance, corporate and other work

•Collaboration and licensing agreements for European, Australian and U.S. life sciences clients with U.S. and European companies, relating to anti-infective, vaccine, drug delivery and other life science technologies.

•Investment due diligence on patents, contracts, executive compensation and deal structure for European venture capital and other investors in U.S. and European companies.

•For a French biotech company, acquisition arrangements relating to a U.S. vaccine company.

•Eight acquisitions in four countries during a twelve-month period for a venture-funded software client with operations in the U.S., Europe and Australia.

•Acquisition of an internet security company from French sellers and (separately) disposition of a different internet security company to a French public buyer, and various financings with investors from France, Australia, the U.S. and Scandinavia.

Central and Eastern Europe (CEEMENA)
Scandinavian & Nordic Region
South Asia

Before Edwards Wildman

After attending Yale University, Al moved to Lusaka, Zambia, for three years of micro-credit activities, primarily as the number two executive of the National Credit Union Association of Zambia. He also has taken post-graduate courses at the University of Ghana, Africa, and the University of Poitiers, France.

Besides Edwards Wildman

Al led a group of corporate executives in a visit to 15-20 large factories in the former Soviet Union in late 1991, traveling down the Volga River via riverboat. Al is an enthusiastic sea kayaker (with four sea kayaks), hiker, and cross-country skier. He is married to a Dane and has two sons.


NCAB Group acquisition of printed circuit board (PCB) operations of M-Wave International, LLC

This was the second such acquisition for which we assisted NCAB. The world's largest outsourced-supplier of PCBs, NCAB is a Swedish technology company having 13 global locations in North America, Europe, and Asia, including China.

Edwards Wildman Represents Boston Dynamics in Its Acquisition by Google

Edwards Wildman represented Boston Dynamics, an MIT robotics spinoff which the firm has advised for two decades, in its acquisition by Google, Inc. Boston Dynamics is renowned for designing legged machines that balance and walk on legs.

Ranovus Class A Financing

An Edwards Wildman team represented Ranovus, Inc. in its $11 million Class A financing.

Novartis Series C Preferred Stock Financing for Akebia

In June 2013, our lawyers represented Novartis Bioventures in a series C preferred stock financing for Akebia Therapeutics, Inc.

Forma Therapeutics Subsequent Round Financing

Our Business Law lawyers represented Forma Therapeutics, Inc. in an amendment to Series C1 Preferred Stock Financing as Enterprise Shares.

Novartis Bioventures Series A

In November 2012, our venture capital team represented Novartis Bioventures along with other investors in a Series A Preferred Stock Financing.

NCAB Group Acquisition of P.D. Circuits, Inc.

An Edwards Wildman team represented NCAB Holding AB of Sweden in its acquisition of P.D. Circuits, Inc., a leading printed circuit boards (PCB) supplier in the United States.

Issuance of Series A1 Preferred Stock

In 2012, our lawyers in Boston with experience in venture capital represented venture fund Novartis Bioventures in the series A1 preferred stock financing of Neurovance, Inc.

Series C1 Preferred Stock Offering for Viamet Pharmaceuticals

In 2012, Edwards Wildman lawyers in Boston and Providence assisted Viamet Pharmaceuticals Holdings, LLC, in closing the first tranche of an equity bridge financing through the sale of Series C1 Shares and warrants to multiple parties.

Forma Therapeutics Series C Preferred Stock Financing

In 2012, a team of lawyers in Boston represented Forma Therapeutics in the Series C1 Preferred Stock financing in portfolio tracking shares to Lilly Ventures and Novartis Bioventures. MORE

Crossing the Pond for a US IPO, BioEquity Europe 2014
Amsterdam, May 2014 event
Survey of All US IPOs by Non-US Biotech Companies, January 2011 - May 2014, BioEquity Europe 2014
Amsterdam, May 2014

Consisting of three and half years of background information and statistics on companies meeting the survey's parameters.
Recalibrating Exit Toolkits for Biotechs, BioEquity Europe 2013
Sweden, May 2013 event
Edwards Wildman Supports World Law Group Survey on Issues and Priorities for Senior In-house Counsel Worldwide
January 22, 2013
Statesman Opinion for Asset-Centric Company Structures
Webinar, November 13, 2012 event
Biotech Start-Ups See Benefits from Changing Structure, Lawyer Says
The Wall Street Journal, August 10, 2012
VC Lifecycle Viewpoint on Optimizing Biotech Companies for Exit
Boston, June 2012 event
Managing Risk between Signing and Closing M&A Deals
Helsinki, June 2012 event
Edwards Wildman Client Advisory - JOBS Act Provides New Opportunities for Private Companies
April 2012
Edwards Wildman Client Advisory - The JOBS Act Makes Significant Changes in the Regulation of Capital Formation and the Compliance Landscape for Many Companies
March 2012

Edwards Wildman Accepts Ice Bucket Challenge, Donates than $5,100 to the ALS Association, Massachusetts Chapter
October 15, 2014
Edwards Wildman Represents Local Robotics Firm in Its Acquisition by Google, Reports Massachusetts Lawyers Weekly
December 19, 2013
Edwards Wildman Advises Boston Dynamics in Its Acquisition by Google, Reports Am Law Daily
December 18, 2013
Edwards Wildman Represents Boston Dynamics in Its Acquisition by Google
December 17, 2013
Edwards Wildman Supports World Law Group Survey on Issues and Priorities for Senior In-house Counsel Worldwide
January 22, 2013
The Wall Street Journal Profiles Al Sokol on the Benefits from Changing the Structure of Biotech Start-ups
August 10, 2012
Firm Hosts First US-Danish Biomedical Innovation and Health Meeting
September 8, 2008
The Firm is Recognized in the American Lawyer
July 7, 2008
Firm Represents Takeda Pharmaceutical Company Limited in $8.8 Billion Acquisition of Millennium Pharmaceuticals
April 10, 2008
EAPD Attorneys Named Super Lawyers 2007
October 30, 2007

Profile Visibility
#50 in weekly profile views out of 19,871 lawyers in Boston, Massachusetts
#3,543 in weekly profile views out of 1,616,736 total lawyers Overall

Office Information

Albert L. Sokol

111 Huntington Avenue
BostonMA 02199-7613


Professional Networking for Legal Professionals Only

Quickly and easily expand your professional
network - join the premier global network for legal professionals only. It's powered by the
Martindale-Hubbell database - over 1,000,000 lawyers strong.
Join Now